Skip to main content
Pharma Mar S.A. logo

Pharma Mar S.A. — Investor Relations & Filings

Ticker · PHM ISIN · ES0169501022 LEI · 959800QWKZ45ZQC2AV58 MC Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2020-06-18 Capital/Financing Update
Country ES Spain
Listing MC PHM

About Pharma Mar S.A.

https://pharmamar.com/en/

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Recent filings

Filing Released Lang Actions
El Consejo de Administración acuerda ejecutar la agrupación y canje de acciones (contra-split) aprobada por la Junta General Ordinaria de Accionistas
Capital/Financing Update Classification · 98% confidence The document is an official communication to the 'Comisión Nacional del Mercado de Valores' (CNMV, the Spanish securities market regulator) dated June 18, 2020. The content explicitly details corporate actions approved by the Shareholders' Meeting, specifically a share consolidation (contra-split) and a capital reduction to facilitate the exchange ratio. These actions directly relate to the company's capital structure and financing arrangements. This fits the definition of 'Capital/Financing Update' (CAP), as it announces changes to the capital structure (share grouping and reduction). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV).
2020-06-18 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 99% confidence The document is titled "STANDARD FORM FOR NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM". This form explicitly details transactions (sales, purchases, etc.) conducted by directors or senior management (PDMRs) of the issuer (PHARMA MAR, S.A.). This directly corresponds to the definition of Director's Dealing, which covers reports of personal share transactions by company directors and executives (insider trades). The corresponding code is DIRS.
2020-06-18 Spanish
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa de Recompra de Acciones en el periodo transcurrido entre el 10 de junio y el 16 de junio de 2020.
Transaction in Own Shares Classification · 98% confidence The document is a formal communication to the 'Comisión Nacional del Mercado de Valores' (Spanish securities market regulator) dated June 17, 2020. The subject is 'Programas de recompra de acciones, estabilización y autocartera' (Share repurchase programs, stabilization, and treasury stock). It details specific 'Compra' (Buy) operations conducted by Pharma Mar, S.A. over a defined period (June 10 to June 16, 2020), including the number of shares and price. This activity directly relates to the company buying back its own shares. According to the definitions, 'Transaction in Own Shares (Code: POS)' covers 'Report of the company buying back or selling its own shares (share repurchase/issuance)'. Although it is a regulatory filing, the specific content points directly to POS rather than the general RNS fallback.
2020-06-17 English
Pharma Mar informa que la FDA ha aprobado lurbinectedina para el tratamiento de cáncer de pulmón microcítico metastásico, bajo la regulación de “accelerated approval”.
Legal Proceedings Report Classification · 99% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV, the Spanish securities market regulator). It is explicitly titled '# **INFORMACIÓN PRIVILEGIADA**' (Inside Information) and announces a significant corporate event: the FDA approval of the drug ZepzelcaTM (lurbinectedin) for PharmaMar. The text details the approval basis, financial implications (payments, royalties), and includes a press release summary. This type of mandatory disclosure of material, non-public information to the regulator strongly indicates a regulatory filing. Given the content is a direct announcement of a major event rather than a periodic financial report (like 10-K or IR) or a transcript, it fits best under the general category for regulatory announcements that are not otherwise specified. Since it is a direct disclosure of material information to the regulator, it is classified as a Regulatory Filing (RNS), which serves as the general category for such mandatory disclosures not covered by more specific codes like DIV or CAP.
2020-06-15 Spanish
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa de Recompra de Acciones en el periodo transcurrido entre el 3 de junio y el 9 de junio de 2020.
Transaction in Own Shares Classification · 98% confidence The document is a formal communication addressed to the Spanish National Securities Market Commission ("Comisión Nacional del Mercado de Valores"). The subject matter is explicitly titled "Programas de recompra de acciones, estabilización y autocartera" (Share repurchase programs, stabilization, and treasury stock) and details transactions conducted under a previously announced Share Repurchase Program between June 3 and June 9, 2020. This activity—the reporting of the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares' (POS). It is not a general insider trade (DIRS), nor is it a general financing update (CAP), but a specific report on treasury share activity.
2020-06-10 Spanish
La Sociedad remite el anuncio complementario al de convocatoria de la Junta General Ordinaria de Accionistas
AGM Information Classification · 98% confidence The document is an official communication to the Spanish National Securities Market Commission (Comisión Nacional del Mercado de Valores) dated June 8, 2020. It explicitly states it is providing 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) and specifically accompanies a 'ANUNCIO COMPLEMENTARIO AL DE CONVOCATORIA DE LA JUNTA GENERAL ORDINARIA DE ACCIONISTAS' (Complementary Announcement to the Call for the Annual General Shareholders' Meeting). The content details the logistics (telematics only) and procedures for the upcoming AGM scheduled for June 17/18, 2020. This document is directly related to the preparation and announcement of the Annual General Meeting (AGM) procedures, making 'AGM Information' (AGM-R) the most appropriate classification, as it is supplementary material for the meeting itself, rather than the final voting results (DVA) or the initial proxy solicitation (PSI).
2020-06-08 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.